CN113854447A - 一种可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料及应用 - Google Patents
一种可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料及应用 Download PDFInfo
- Publication number
- CN113854447A CN113854447A CN202110913300.9A CN202110913300A CN113854447A CN 113854447 A CN113854447 A CN 113854447A CN 202110913300 A CN202110913300 A CN 202110913300A CN 113854447 A CN113854447 A CN 113854447A
- Authority
- CN
- China
- Prior art keywords
- medlar
- gout
- hyperuricemia
- fermented beverage
- probiotic fermented
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000017784 Mespilus germanica Nutrition 0.000 title claims abstract description 71
- 235000000560 Mimusops elengi Nutrition 0.000 title claims abstract description 71
- 235000007837 Vangueria infausta Nutrition 0.000 title claims abstract description 71
- 239000006041 probiotic Substances 0.000 title claims abstract description 71
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 71
- 235000019985 fermented beverage Nutrition 0.000 title claims abstract description 45
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 45
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 42
- 201000005569 Gout Diseases 0.000 title claims abstract description 33
- 240000002624 Mespilus germanica Species 0.000 title claims 13
- 238000000855 fermentation Methods 0.000 claims abstract description 31
- 230000004151 fermentation Effects 0.000 claims abstract description 31
- 235000013361 beverage Nutrition 0.000 claims abstract description 27
- 230000006378 damage Effects 0.000 claims abstract description 14
- 230000001954 sterilising effect Effects 0.000 claims abstract description 13
- 230000036541 health Effects 0.000 claims abstract description 12
- 210000004185 liver Anatomy 0.000 claims abstract description 10
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 6
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 5
- 238000001816 cooling Methods 0.000 claims abstract description 5
- 208000014674 injury Diseases 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 21
- 238000011081 inoculation Methods 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 16
- 239000000047 product Substances 0.000 claims description 14
- 241000191998 Pediococcus acidilactici Species 0.000 claims description 13
- 244000199866 Lactobacillus casei Species 0.000 claims description 12
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 12
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 12
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 12
- 229940017800 lactobacillus casei Drugs 0.000 claims description 12
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 230000003907 kidney function Effects 0.000 claims description 8
- 238000003860 storage Methods 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 5
- 230000003908 liver function Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 241000607479 Yersinia pestis Species 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000004537 pulping Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 239000008223 sterile water Substances 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 2
- 244000182216 Mimusops elengi Species 0.000 abstract description 58
- 244000241838 Lycium barbarum Species 0.000 abstract description 13
- 235000015459 Lycium barbarum Nutrition 0.000 abstract description 13
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 abstract description 12
- 210000003734 kidney Anatomy 0.000 abstract description 12
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 11
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 10
- 229940116269 uric acid Drugs 0.000 abstract description 10
- 150000004666 short chain fatty acids Chemical class 0.000 abstract description 7
- 235000015468 Lycium chinense Nutrition 0.000 abstract description 6
- 229940109239 creatinine Drugs 0.000 abstract description 6
- 230000006870 function Effects 0.000 abstract description 6
- 230000001575 pathological effect Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 3
- 229930006000 Sucrose Natural products 0.000 abstract description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract description 3
- 235000020510 functional beverage Nutrition 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract description 2
- 238000004458 analytical method Methods 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 235000003599 food sweetener Nutrition 0.000 abstract description 2
- 235000013572 fruit purees Nutrition 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 239000004310 lactic acid Substances 0.000 abstract description 2
- 235000014655 lactic acid Nutrition 0.000 abstract description 2
- 230000036542 oxidative stress Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 229960004793 sucrose Drugs 0.000 abstract description 2
- 239000003765 sweetening agent Substances 0.000 abstract description 2
- 238000007781 pre-processing Methods 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 26
- 230000000694 effects Effects 0.000 description 18
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
- 230000004044 response Effects 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 235000013305 food Nutrition 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000011344 liquid material Substances 0.000 description 6
- 208000030159 metabolic disease Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 210000005084 renal tissue Anatomy 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 235000021391 short chain fatty acids Nutrition 0.000 description 4
- RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 244000241872 Lycium chinense Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 235000012055 fruits and vegetables Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002068 microbial inoculum Substances 0.000 description 3
- 229950000193 oteracil Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 235000021395 porridge Nutrition 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010206 sensitivity analysis Methods 0.000 description 1
- 239000004460 silage Substances 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000000053 special nutrition Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/41—Pediococcus
- A23V2400/413—Acidilactici
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料,所述饮料的制备步骤如下:枸杞预处理;灭菌后,立刻冷却;给灭菌后的枸杞接种益生菌;将接种后的枸杞放入生化培养箱进行恒温发酵,即得成品饮料。本发明饮料综合了枸杞和益生菌的保健功能,发明出一种可有效缓解高尿酸血症及痛风症状的功能性饮品,具有广阔的应用前景。经过发酵转化后,枸杞原浆增添了独特的乳酸风味,分析表明饮料中活性益生菌以及短链脂肪酸等活性物质得以富集,细胞及动物水平的药理学评价显示能够显著改善高尿酸血症及痛风中的血清尿酸、肌酐、肝肾病理损伤、炎症及氧化应激等症状,且本发明不添加蔗糖等甜味剂,进一步满足了消费者对于低糖健康食品的需求。
Description
技术领域
本发明属于生物与医药、食品技术领域,涉及饮料,尤其是一种可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料及应用。
背景技术
高尿酸血症(HUA)是一种由嘌呤代谢紊乱引起的、以血清尿酸水平升高为主要特征的代谢病。近年来,随着人们生活水平的不断提高及饮食结构的改变,特别是高嘌呤饮食的增加,HUA呈现年轻化趋势。截至2017年底,我国确诊病例已达1.7亿例。尽管HUA不属于致命性疾病,但是当血尿酸超过饱和浓度时,尿酸盐晶体析出可直接沉积在关节、软骨、输尿管等处,从而引起人体局部组织的无菌性炎症反应,进而引起痛风。此外,HUA还与糖尿病、高脂血症、非酒精性脂肪肝等多种高发性代谢疾病有关,最新研究表明,HUA还与多种癌症的发病率和死亡率相关。
人体内的尿酸,约70%通过肾脏排泄,其余随粪便排出或经肠道菌群进一步分解代谢。少部分在人体肠道内排泄或由肠道内菌群分解。目前,传统的治疗高尿酸血症的药物主要为排尿酸药、抑制尿酸生成药和碱性药物,包括别嘌呤醇、苯溴马隆、非布司他等。但上述药物均存在副作用过多的问题,且代谢类疾病需要漫长的防控调理,在患者普遍存在肝肾功能衰退的情况下,长期用药无疑是“伤敌一千、自损八百”,因此,探究并发掘调理、改善肝肾功能的药食两用产品,具有重要的社会意义。
枸杞是我国传统中药材和功能性食品添加剂,在中国食用枸杞已有2000多年的历史。《本草汇言》记载:“枸杞能使气可充,血可补,阳可生,阴可长,火可降,风湿可去,有十全之妙用焉”,意为枸杞用作中药时,具有滋补肝肾、益精明目的功效,主治目眩昏暗、肾虚腰痛等症状;《本草纲目》也记载:“久服坚筋骨”,表明长期服用枸杞,可以扶正固本、滋阴补肾。民间关于枸杞的传统中药验方包括金髓煎、四神丸、地杞沉香酒等,都具有补肾助阳的功效。现代医学研究表明,枸杞可降低血糖、胆固醇及甘油三酯水平,对脂肪肝、糖尿病和心血管疾病患者有一定的疗效,此外,枸杞还可治疗慢性肾衰竭。
近年来,国内饮料市场蓬勃发展,茶饮料、果蔬汁原浆和功能性饮料占据较大比重。其中,为了迎合消费者的健康理念,发酵制品正在不断走向成熟。现如今,益生菌被广泛地应用于食品行业,其依靠对人体特殊的神奇功效,得到了广大消费者的普遍认可。采用益生菌生物发酵技术开发具有特殊营养保健功能的发酵饮料,特别是对于许多药食同源性、营养健康功效显著的果蔬或植物性材料,通过益生菌的发酵不但可以获得更加丰富的口感,而且可以获得比单纯的果蔬汁原浆更为理想的保健功能。
通过检索,发现如下几篇关于制备染料分散剂方面的相关专利公开文献,具体如下:
一种枸杞益生菌发酵饮料及其制备方法(CN110074299A),是由下列重量成分组成:大米120-180公斤,枸杞子30-50公斤,白糖30-70公斤,果糖40-60公斤,三氯蔗糖50-60克,山梨酸钾1-2公斤,柠檬酸0.1-1公斤,盐0.1-0.5公斤,嗜热链球菌100-300克,嗜酸乳杆菌150-250克,两岐双岐杆菌150-200克。本发明具有如下优点:口感上佳,提高机体免疫功能,增强机体适应调节能力,具有抗癌作用,具有显著的明目作用,提升精力,增强学习记忆,提高肌体适应性,增强人体造血功能,延缓衰老,美容养颜,降血脂降血压,治疗男性不育,强身壮阳,缓解过敏性炎症,保肝、防脂肪肝,降血糖,治疗糖尿病,治疗慢性肝炎、肝硬化。
通过对比,本发明专利申请与上述专利公开文献存在本质的不同。
发明内容
本发明目的在于克服现有技术中的不足之处,提供一种可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料及应用。
本发明解决其技术问题所采用的技术方案是:
一种可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料,所述饮料的制备步骤如下:
(1)枸杞预处理:挑选无病虫害、无机械损伤的新鲜枸杞子,利用无菌水清洗干净并沥干水分,于-30℃至-25℃环境下破碎打浆,最后巴氏灭菌消毒并密封保存,即得到成品枸杞原浆;用去离子水将枸杞原浆稀释九倍,备用;
(2)灭菌:灭菌条件为55-70℃、20-40min,灭菌后,立刻冷却至4-5℃;
(3)接种:给灭菌后的枸杞接种益生菌;
(4)恒温发酵:将接种后的枸杞放入生化培养箱进行恒温发酵,25-40℃、5-12h,即得成品饮料。
进一步地,所述步骤(1)中巴氏灭菌消毒灌装至密封袋中保存。
进一步地,所述步骤(3)中益生菌为植物乳杆菌CGMCC8198、乳酸片球菌LTJ28和/或干酪乳杆菌YR2-2,均符合国家2010年发布的《可用于食品的菌种名单》要求的益生菌菌株。
进一步地,所述步骤(3)中益生菌为植物乳杆菌CGMCC8198、乳酸片球菌LTJ28、干酪乳杆菌YR2-2以体积比1:1:2的比例复配发酵,其中,各个菌的浓度不少于108CFU/mL。
进一步地,所述步骤(3)中益生菌的接种量为3-6%。
进一步地,所述益生菌的接种量为4%。
进一步地,所述益生菌菌株在-80℃保存后,须过夜活化8-15h,活菌数为108CFU/mL以上后,进行接种。
如上所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料在制备用于改善肝肾功能损伤的药品或保健品方面中的应用。
如上所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料在制备用于预防或治疗高尿酸血症的药品和保健品方面中的应用。
如上所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料在制备用于预防或治疗痛风的药品和/或保健品方面中的应用。
本发明取得的优点和积极效果为:
1、本发明通过前期研究表明,所选取的三种不同来源的益生菌都具备较好的益生效果。从青贮饲料中筛选得到的植物乳杆菌8198,具有很强的耐酸耐胆盐能力,通过《植物乳杆菌在降血脂和辅助减肥方面的应用》(CN103598594A)已经证实,植物乳杆菌8198在降血脂和降胆固醇方面有一定的效果,具有辅助减肥的功效;《一株具有优良抗酒精胁迫能力的乳酸片球菌和应用》(CN111944713A)公开了乳酸片球菌LTJ28优良的抗酒精胁迫能力,以及该菌株在食品加工领域深远的应用前景;干酪乳杆菌YR2-2来源于酸粥,《酸粥类食品中乳杆菌的药敏性分析及优势菌株的筛选》已经证实,干酪乳杆菌安全性相对较高,是一种理想的发酵剂。由于不同菌种之间存在共生作用,复合菌剂的抗氧化能力往往优于单菌种发酵,因此本发明融合了三种益生菌的不同功效,这对探究代谢病等慢性疾病的治疗大有裨益。
2、本发明饮料使用的枸杞富含花青素、类胡萝卜素、多酚、黄酮和多糖等多种特殊成分,可提高机体抗氧化能力,具有滋阴补肾、延缓衰老等积极作用。本发明饮料综合了枸杞和益生菌的保健功能,发明出一种可有效缓解高尿酸血症及痛风症状的功能性饮品,具有广阔的应用前景。经过发酵转化后,枸杞原浆增添了独特的乳酸风味,分析表明饮料中活性益生菌以及短链脂肪酸等活性物质得以富集,细胞及动物水平的药理学评价显示能够显著改善高尿酸血症及痛风中的血清尿酸、肌酐、肝肾病理损伤、炎症及氧化应激等症状,且本发明不添加蔗糖等甜味剂,进一步满足了消费者对于低糖健康食品的需求。
3、体外实验表明,经过发酵工艺单因素及响应面的优化,所制得的上述枸杞益生菌发酵饮料,其活性益生菌数量以及抗氧化性较发酵前得到明显提高,且该饮料富含活的益生菌,有广泛的接受度和市场前景,这为枸杞益生菌发酵饮料的工业化生产提供了最佳参数。
4、体内实验表明,对小鼠腹腔注射氧嗪酸钾并辅以高嘌呤饮食建立高尿酸血症模型,经30d造模成功后,饮料组小鼠血尿酸、肌酐和尿素氮水平显著降低,同时观察小鼠的肾脏病理切片也发现,该饮料可改善高尿酸血症的肾脏组织和细胞形态,显示该饮料在一定程度上能缓解肝肾病理性损伤,且小鼠肠道短链脂肪酸丰度较对照组小鼠明显升高,这证明了该饮料起到了改善肠道功能、保护肠道健康的作用。这对减轻高嘌呤饮食引起的高尿酸血症、痛风等慢性代谢疾病具有重要的现实意义。
附图说明
图1为本发明枸杞益生菌发酵饮料的一种工艺流程示意图;
图2为本发明中维生素C的DPPH自由基清除能力标准曲线;
图3为本发明中发酵条件的单因素实验结果图;其中,上方图片从左至右依次为发酵时间、发酵温度和发酵液料比的单因素实验结果图,下方图片中的左图为菌种接种量的单因素实验结果图,右图为菌种配比(植物乳杆菌8198:乳酸片球菌LTJ28:干酪乳杆菌YR2-2)的单因素实验结果图;
图4为本发明中响应面试验结果图;其中,图片从前到后依次为发酵时间和接种量对评分影响的响应面与等高线图、发酵时间和液料比对评分影响的响应面与等高线图、接种量和液料比对评分影响的响应面与等高线图;
图5为本发明中枸杞益生菌发酵饮料对小鼠肾功能的影响图;其中,图片从左到右依次为不同组小鼠尿酸水平结果图、不同组小鼠尿素氮水平结果图、不同组小鼠肌酐水平结果图;
图6为本发明中不同组小鼠肾脏病理切片图;其中,图片从前到后依次为正常组(NC)、模型组(M)、枸杞组(GQ)、枸杞饮料组(YL);
图7为本发明中枸杞益生菌发酵饮料对小鼠短链脂肪酸含量的影响图;其中,图片从左到右依次为不同组小鼠肠道乙酸含量图、不同组小鼠肠道丙酸含量图、不同组小鼠肠道丁酸含量图。
具体实施方式
下面详细叙述本发明的实施例,需要说明的是,本实施例是叙述性的,不是限定性的,不能以此限定本发明的保护范围。
本发明中所使用的原料,如无特殊说明,均为常规的市售产品;本发明中所使用的方法,如无特殊说明,均为本领域的常规方法。
一种可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料,所述饮料的制备步骤如下:
(1)枸杞预处理:挑选无病虫害、无机械损伤的新鲜枸杞子,利用无菌水清洗干净并沥干水分,于-30℃至-25℃环境下破碎打浆,最后巴氏灭菌消毒并密封保存,即得到成品枸杞原浆;用去离子水将枸杞原浆稀释九倍,备用;
(2)灭菌:灭菌条件为55-70℃、20-40min,灭菌后,立刻冷却至4-5℃;
(3)接种:给灭菌后的枸杞接种益生菌;
(4)恒温发酵:将接种后的枸杞放入生化培养箱进行恒温发酵,25-40℃、5-12h,即得成品饮料。
较优地,所述步骤(1)中巴氏灭菌消毒灌装至密封袋中保存。
较优地,所述步骤(3)中益生菌为植物乳杆菌CGMCC8198、乳酸片球菌LTJ28和/或干酪乳杆菌YR2-2,均符合国家2010年发布的《可用于食品的菌种名单》要求的益生菌菌株。
较优地,所述步骤(3)中益生菌为植物乳杆菌CGMCC8198、乳酸片球菌LTJ28、干酪乳杆菌YR2-2以体积比1:1:2的比例复配发酵,其中,各个菌的浓度不少于108CFU/mL。
较优地,所述步骤(3)中益生菌的接种量为3-6%。
较优地,所述益生菌的接种量为4%。
较优地,所述益生菌菌株在-80℃保存后,须过夜活化8-15h,活菌数为108CFU/mL以上后,进行接种。
如上所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料在制备用于改善肝肾功能损伤的药品或保健品方面中的应用。
如上所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料在制备用于预防或治疗高尿酸血症的药品和保健品方面中的应用。
如上所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料在制备用于预防或治疗痛风的药品和/或保健品方面中的应用。
具体地,相关制备及检测实施例如下:
实施例1
如图1所示,制备一种可缓解高尿酸血症及痛风患者肾功能损伤的枸杞益生菌发酵饮料,包括以下步骤:
步骤一、枸杞预处理:用纯净水将枸杞原浆稀释,体积比为8:1;
步骤二、灭菌:巴氏灭菌条件为68℃、30min,灭菌后,立刻冷却至4-5℃;
步骤三、接种:给灭菌后的枸杞接种植物乳杆菌8198、乳酸片球菌LTJ28和干酪乳杆菌YR2-2;
步骤四、恒温发酵:将接种后的枸杞放入37℃生化培养箱恒温发酵7.5h,即得成品饮料。
实施例2
不同益生菌与枸杞的协同作用实验:
配制0.2、0.4、0.6、0.8、1mmol/L的维生素C溶液,分别取0.2mL与2.8mL 0.2mmol/LDPPH工作液均匀混合,摇匀,避光静置30min,并在517nm处测其吸光值。以维生素C浓度为横坐标,测得的吸光值为纵坐标,制作维生素C标准曲线。结果如图2所示。图中R2>0.99,说明此标准曲线具有良好的线性关系,该测定方法具有可信度。
为探索不同菌种发酵枸杞的抗氧化能力的差异,分别取0.2mL不同发酵液,按照上述实验方法并利用回归方程计算维生素C当量。结果如表1所示,未发酵枸杞的抗氧化能力相当于597.133μmol/L的维生素C,经过植物乳杆菌8198发酵后,抗氧化性可提升25.12%;经过乳酸片球菌LTJ28发酵后,抗氧化性可提升18.24%;经过干酪乳杆菌YR2-2发酵后,抗氧化性可提升31.37%;而经过三种益生菌以体积比1:1:1的比例复配发酵后,其中,各个菌的浓度不少于108cfu/ml,其抗氧化性提升35.34%,可以看出,植物乳杆菌CGMCC8198、乳酸片球菌LTJ28、干酪乳杆菌YR2-2具有协同作用,复合菌剂的抗氧化能力显著优于单菌种发酵。可见利用三种复配菌株发酵枸杞具有一定的研究意义,对其发酵条件进行一系列的优化,并探究体内外的功效活性,都将为枸杞益生菌饮料的标准化生产提供理论支持。
表1不同菌种发酵枸杞的维C当量
实施例3
检测枸杞益生菌发酵饮料的抗氧化性和活菌数:
(1)配置0.2mmol/LDPPH工作液,将1.0mL发酵液与1.0mLDPPH溶液以及3.0mL二级水加入同一试管中,摇匀,避光静置30min,并在517nm处测量其吸光值。并按下式计算其清除率:
清除率=[1-(AX-AX0)]/A0×100%
AX:1.0mL发酵液+1.0mLDPPH+3.0mL蒸馏水
A0:1.0mLDPPH+4.0mL蒸馏水
AX0:5.0mL无水乙醇
(2)将发酵饮料以10的倍数依次递增稀释,取3个合适的稀释度(10-8、10-9、10-10),吸取100μL稀释液于MRS培养基涂布均匀,每个稀释度做两平行,37℃培养36h后计数。
实施例4
以表2中的评分细则为指标,分别以图2的五个因素对枸杞益生菌发酵饮料进行优化。之后,在单因素实验的基础上,利用响应面法对液料比、发酵时间和接种量进行Box-Behnken Design设计,试验方案如表3所示。
通过Design-Expert.10软件对得出的实验数据进行分析,建立了该工艺条件的模型。在保证发酵时间、接种量与液料比三个因素中一个因素不变的情况下,得到其他因素的三维响应面和等高线。不同因素之间的交互作用的响应面和等高线具体如图3所示。响应面越陡,等高线越密集,表明因素之间的交互作用越明显。从响应面曲线可以看出,交互作用为AC>AB>BC,说明发酵时间和液料比对枸杞益生菌发酵饮料的评分影响最为显著,而接种量和液料比对枸杞益生菌发酵饮料的评分影响相对较弱。此外,建立枸杞益生菌发酵饮料的二次多项式回归方程,模型回归系数显著性检验结果如表4所示,模型P<0.01,显著,失拟项P>0.05,不显著,表明该模型拟合程度较好,可以根据试验结果对最优条件进行预测,并运用该模型进行最优工艺条件预测。
表2枸杞益生菌发酵饮料的评分细则
表3响应面试验设计及结果
表4响应面模型回归显著性检验结果
实施例5
检测枸杞益生菌发酵饮料对小鼠肾功能的影响:
动物实验:
采用腹腔注射氧嗪酸钾并辅以高嘌呤饮食建立高尿酸血症小鼠模型,实验动物采用雄性昆明小鼠20只,在室温下饲养,自由饮食采食,经1周适应性饲养后,随机分成正常对照组(NC)、高尿酸血症模型组(M)、枸杞原浆治疗组(GQ)和枸杞益生菌发酵饮料治疗组(YL),每组5只。除正常对照组外,其他三组小鼠按300mg/kg·d标准腹腔注射氧嗪酸钾-羧甲基纤维素钠混悬液,并按照10g/kg·d标准进行酵母膏灌胃,此外NC和M组小鼠按照0.2mL/d标准灌胃生理盐水,GQ和YL组小鼠按照0.2mL/d标准灌胃枸杞原浆和枸杞益生菌发酵饮料,持续30d。
如图5所示,实验数据表明,连续腹腔注射氧嗪酸钾并佐以高嘌呤饮食30d后,M组、GQ组和YL组小鼠血尿酸、肌酐和尿素氮含量较正常组小鼠均显著升高,而通过枸杞及枸杞饮料的干预,小鼠血尿酸水平明显下降,肌酐与尿素氮水平与M组小鼠相比也显著降低,且枸杞饮料的效果要优于单纯的枸杞原浆,这说明枸杞益生菌发酵饮料具有补肾益肾的效果。
取新鲜小鼠肾脏组织,用10%多聚甲醛固定过夜,并进行脱水透明、浸蜡包埋、切片与贴片和脱蜡染色等步骤。观察发现,如图6所示,正常组小鼠肾小球结构完整,肾小管清晰可见,肾细胞排列较为整齐;模型组小鼠肾脏组织细胞核聚集,出现肾间质炎性细胞浸润,且远端肾小管扩张、管腔增大,并有肾小管上皮细胞空泡化的趋势;与模型组相比,枸杞及饮料组小鼠的空泡细胞显著减少,肾脏组织结构也基本趋于正常。这表明了枸杞及枸杞饮料均有不同程度的改善肾脏组织和细胞形态的作用。
实施例6
采用气相色谱法测定枸杞益生菌发酵饮料对小鼠肠道短链脂肪酸的影响:
样品处理:
取0.2g小鼠结肠内容物加1mL蒸馏水混匀,并以13000rpm的速度离心10min后取200μL上清液,在上清液中分别加入100μL10%硫酸溶液和1mL乙酸乙酯,并涡旋振荡5min,最后以13000rpm的速度离心10min,取上清液过0.22μm微孔滤膜后待用。
气相色谱条件:
进样量:1μL
进样口温度(加热器):250℃
色谱柱:HP-5
长度30cm×内径320μm×膜厚0.25μm
柱流速:2mL/min
柱温:初始柱温:90℃,保持6min
以10℃/min的速度升温至200℃,保留6min
检测器:
加热器:250℃
H2流量:30mL/min
空气流量:300mL/min
如图7所示,实验数据表明,通过30d枸杞益生菌发酵饮料的干预,小鼠肠道乙酸和丙酸水平较正常组小鼠明显升高,而丁酸效果不明显。乙酸等短链脂肪酸是肠道菌群利用膳食纤维发酵而得的产物,枸杞益生菌发酵饮料能够提高肠道短链脂肪酸的丰度,说明了枸杞饮料具有保护肠屏障、改善肠道功能、维持肠道健康的作用。
尽管为说明目的公开了本发明的实施例,但是本领域的技术人员可以理解:在不脱离本发明及所附权利要求的精神和范围内,各种替换、变化和修改都是可能的,因此,本发明的范围不局限于实施例所公开的内容。
Claims (10)
1.一种可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料,其特征在于:所述饮料的制备步骤如下:
(1)枸杞预处理:挑选无病虫害、无机械损伤的新鲜枸杞子,利用无菌水清洗干净并沥干水分,于-30℃至-25℃环境下破碎打浆,最后巴氏灭菌消毒并密封保存,即得到成品枸杞原浆;用去离子水将枸杞原浆稀释九倍,备用;
(2)灭菌:灭菌条件为55-70℃、20-40min,灭菌后,立刻冷却至4-5℃;
(3)接种:给灭菌后的枸杞接种益生菌;
(4)恒温发酵:将接种后的枸杞放入生化培养箱进行恒温发酵,25-40℃、5-12h,即得成品饮料。
2.根据权利要求1所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料,其特征在于:所述步骤(1)中巴氏灭菌消毒灌装至密封袋中保存。
3.根据权利要求1所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料,其特征在于:所述步骤(3)中益生菌为植物乳杆菌CGMCC8198、乳酸片球菌LTJ28和/或干酪乳杆菌YR2-2。
4.根据权利要求1所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料,其特征在于:所述步骤(3)中益生菌为植物乳杆菌CGMCC8198、乳酸片球菌LTJ28、干酪乳杆菌YR2-2以体积比1:1:2的比例复配发酵,其中,各个菌的浓度不少于108CFU/mL。
5.根据权利要求1所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料,其特征在于:所述步骤(3)中益生菌的接种量为3-6%。
6.根据权利要求5所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料,其特征在于:所述益生菌的接种量为4%。
7.根据权利要求1至6任一项所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料,其特征在于:所述益生菌菌株在-80℃保存后,须过夜活化8-15h,活菌数为108CFU/mL以上后,进行接种。
8.如权利要求1至7任一项所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料在制备用于改善肝肾功能损伤的药品或保健品方面中的应用。
9.如权利要求1至7任一项所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料在制备用于预防或治疗高尿酸血症的药品和保健品方面中的应用。
10.如权利要求1至7任一项所述的可缓解高尿酸血症及痛风的枸杞益生菌发酵饮料在制备用于预防或治疗痛风的药品和/或保健品方面中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110913300.9A CN113854447B (zh) | 2021-08-10 | 2021-08-10 | 一种枸杞益生菌发酵饮料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110913300.9A CN113854447B (zh) | 2021-08-10 | 2021-08-10 | 一种枸杞益生菌发酵饮料 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113854447A true CN113854447A (zh) | 2021-12-31 |
CN113854447B CN113854447B (zh) | 2024-01-12 |
Family
ID=78990431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110913300.9A Active CN113854447B (zh) | 2021-08-10 | 2021-08-10 | 一种枸杞益生菌发酵饮料 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113854447B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118109376A (zh) * | 2024-04-30 | 2024-05-31 | 晏龙国科(山东)微生物科技有限公司 | 一种用于治疗高尿酸血症和痛风的中药发酵液及其应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004112809A1 (ja) * | 2003-06-24 | 2004-12-29 | Otsuka Pharmaceutical Co., Ltd. | 血清尿酸低減組成物 |
US20110014168A1 (en) * | 2007-11-29 | 2011-01-20 | Meiji Dairies Corporation | Lactic acid bacteria having action of lowering blood uric acid level |
CN105167072A (zh) * | 2015-08-02 | 2015-12-23 | 周学义 | 一种功能性枸杞酵素及其制品的生产方法 |
CN106387572A (zh) * | 2016-08-30 | 2017-02-15 | 宁夏沃福百瑞枸杞产业股份有限公司 | 一种枸杞益生菌饮料及其制备方法 |
CN108703218A (zh) * | 2018-05-24 | 2018-10-26 | 南京小洋人生物科技发展有限公司 | 一种抑制嘌呤吸收的发酵型乳酸菌饮料的制备方法 |
CN108902949A (zh) * | 2018-07-30 | 2018-11-30 | 山东晨彰生物科技有限公司 | 一种具有预防痛风功能的酵素及其制备方法 |
WO2019203827A1 (en) * | 2018-04-19 | 2019-10-24 | Kibow Biotech Inc . | Composition and method for preventing or treating hyperuricemia or gout |
CN113174341A (zh) * | 2021-03-25 | 2021-07-27 | 天津科技大学 | 一种源于枸杞酵素的具有降尿酸功效的乳酸片球菌及其应用 |
-
2021
- 2021-08-10 CN CN202110913300.9A patent/CN113854447B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004112809A1 (ja) * | 2003-06-24 | 2004-12-29 | Otsuka Pharmaceutical Co., Ltd. | 血清尿酸低減組成物 |
US20110014168A1 (en) * | 2007-11-29 | 2011-01-20 | Meiji Dairies Corporation | Lactic acid bacteria having action of lowering blood uric acid level |
CN105167072A (zh) * | 2015-08-02 | 2015-12-23 | 周学义 | 一种功能性枸杞酵素及其制品的生产方法 |
CN106387572A (zh) * | 2016-08-30 | 2017-02-15 | 宁夏沃福百瑞枸杞产业股份有限公司 | 一种枸杞益生菌饮料及其制备方法 |
WO2019203827A1 (en) * | 2018-04-19 | 2019-10-24 | Kibow Biotech Inc . | Composition and method for preventing or treating hyperuricemia or gout |
CN108703218A (zh) * | 2018-05-24 | 2018-10-26 | 南京小洋人生物科技发展有限公司 | 一种抑制嘌呤吸收的发酵型乳酸菌饮料的制备方法 |
CN108902949A (zh) * | 2018-07-30 | 2018-11-30 | 山东晨彰生物科技有限公司 | 一种具有预防痛风功能的酵素及其制备方法 |
CN113174341A (zh) * | 2021-03-25 | 2021-07-27 | 天津科技大学 | 一种源于枸杞酵素的具有降尿酸功效的乳酸片球菌及其应用 |
Non-Patent Citations (1)
Title |
---|
汪云阳;单静博;陈亚楠;乔长晟;罗学刚;: "枸杞发酵饮料的工艺优化及其风味物质分析", 食品研究与开发, no. 18, pages 40 - 47 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118109376A (zh) * | 2024-04-30 | 2024-05-31 | 晏龙国科(山东)微生物科技有限公司 | 一种用于治疗高尿酸血症和痛风的中药发酵液及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113854447B (zh) | 2024-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109666615A (zh) | 一种益生菌组合物及其应用 | |
CN103908585B (zh) | 用于预防和治疗便秘的益生菌发酵组合物 | |
CN102934809B (zh) | 益生菌发酵中药制剂制备的组合物及其制备方法和应用 | |
CN104957610B (zh) | 一种植物酵素及其制备方法和用途 | |
CN102845695B (zh) | 一种魔芋发酵食饮品及其制备方法 | |
CN106729092A (zh) | 一种含低聚木糖的降血脂制剂及其制备方法和应用 | |
CN107752024A (zh) | 一种改善三高及肥胖等代谢异常疾病的营养代餐食品 | |
CN110558463A (zh) | 一种预防和控制糖尿病的益生菌发酵饮料及其制备方法 | |
CN106962937A (zh) | 制备具有预防调理高血压、高血脂、高血糖及日常养护功效植物酵素的发酵组合物及制法 | |
CN109528814A (zh) | 一种乳酸菌发酵黄芪的微生态制剂及其制备方法和应用 | |
JP3644500B2 (ja) | キノコ乳酸発酵液の製造方法及びそれから製造されるキノコ乳酸発酵液(amethodforpreparingalacticacidfermentedsolutionofmushroomandlacticacidfermentedsolutionofmushroomproducedthereby) | |
CN103798494B (zh) | 健胃益脾红茶菌山楂糕及其制作方法 | |
CN107751703A (zh) | 一种具有调节肠道菌群功能的固体饮料及其检测方法 | |
CN113854447B (zh) | 一种枸杞益生菌发酵饮料 | |
CN106360683A (zh) | 一种铁皮石斛香蕉复合益生菌发酵产品及其方法 | |
CN110547447A (zh) | 一种蜂王浆胶原蛋白水果酵素及其制作方法 | |
CN109170863A (zh) | 一种功能糖酵素及其制备方法 | |
CN107375466A (zh) | 一种具有降血脂功能的药食两用发酵液及其制备方法 | |
CN112042835A (zh) | 一种具有降血脂作用的非全营养特医食品及其制备方法 | |
CN107095300A (zh) | 一种辅助治疗糖尿病的生物营养配方组合物 | |
CN107296188A (zh) | 一种柚子饮料及其制备方法 | |
CN114304609B (zh) | 一种具有降脂功效的玫瑰花酵素及其制备方法 | |
CN105176773A (zh) | 一种调节血糖的南瓜酒及其制作方法 | |
CN101669623A (zh) | 一种适合糖尿病人的饮料或口服液及其制备方法 | |
CN114304620A (zh) | 一种复合菌发酵的新疆药桑葚复合酵素及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |